La vía de la insulina y el factor de crecimiento similar a la insulina, una nueva diana terapéutica en oncología
DOI:
https://doi.org/10.23938/ASSN.0137Palabras clave:
Factor de crecimiento similar a la insulina I. Factor de crecimiento similar a la insulina II. Receptor de la insulina. Receptores relacionados con el receptor de la insulina.Resumen
La biología molecular del cáncer ha permitido identificar nuevas dianas para atacar las células tumorales. Recientemente se ha propuesto la vía de señalización de la insulina y el factor de crecimiento similar a la insulina como una de estas dianas. En esta revisión se describe su función biológica, los datos de laboratorio y estudios poblacionales que alertan de su papel en el cáncer y se describen los elementos claves de esta vía de señalización: los ligandos (insulina, IGF1, IGF2), sus receptores y la cascada de señales intracelular que desencadena su activación. Así mismo se revisan las distintas estrategias que se están investigando para bloquearla, algunas de las cuales ya se encuentran en estudios avanzados fase III. Los datos preliminares indican que los fármacos diseñados para bloquear esta vía pueden ser una nueva arma terapéutica para los pacientes oncológicos en un futuro próximo.Descargas
Citas
1. CHAN SJ, STEINER DF. Insulin through the ages: phylogeny of a growth promoting and metabolic regulatory hormone. American Zoologist 2000; 40: 213-222.
https://doi.org/10.1093/icb/40.2.213
2. DONG MQ, VENABLE JD, AU N, XU T, PARK SK, COCIORVA D et al. Quantitative mass spectrometry identifies insulin signaling targets in C. elegans. Science 2007; 317: 660-663.
https://doi.org/10.1126/science.1139952
3. TOYOSHIMA Y, MONSON C, DUAN C, WU Y, GAO C, YAKAR S et al. The role of insulin receptor signaling in zebrafish embryogenesis. Endocrinology 2008; 149: 5996-6005.
https://doi.org/10.1210/en.2008-0329
4. EVANS JM, DONNELLY LA, EMSLIE-SMITH AM, ALESSI DR, MORRIS AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-1305.
https://doi.org/10.1136/bmj.38415.708634.F7
5. BURGESS AW. EGFR family: structure physiology signalling and therapeutic targets. Growth Factors 2008; 26: 263-274.
https://doi.org/10.1080/08977190802312844
6. RAJU TN. A mysterious something: the discovery of insulin and the 1923 Nobel Prize for Frederick G. Banting (1891-1941) and John J.R. Macleod (1876-1935). Acta Paediatr 2006; 95: 1155-1156.
https://doi.org/10.1080/08035250600930328
7. SALMON WD JR, DAUGHADAY W. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 1957; 49: 825-836
8. LARON Z. The somatostatin-GHRH-GH-IGF-I axis. En: Merimee T, Laron Z, eds. Growth hormone, IGF-I and growth: new views of old concepts. Modern endocrinology and diabetes, Vol. 4. London-Tel Aviv: Freund Publishing House Ltd, 1996: 5-10.
9. BERG U, BANG P. Exercise and circulating insulin-like growth factor I. Horm Res 2004; 62 Suppl. 1: 50-58.
https://doi.org/10.1159/000080759
10. FIRTH SM, BAXTER RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23: 824-854.
https://doi.org/10.1210/er.2001-0033
11. BUCKBINDER L, TALBOTT R, VELASCO-MIGUEL S, TAKENAKA I, FAHA B, SEIZINGER BR et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995; 377: 646-649.
https://doi.org/10.1038/377646a0
12. MEHRIAN-SHAI R, CHEN CD, SHI T, HORVATH S, NELSON SF, REICHARDT JK et al. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A 2007; 104: 5563-5568.
https://doi.org/10.1073/pnas.0609139104
13. ZHU W, SHIOJIMA I, ITO Y, LI Z, IKEDA H, YOSHIDA M et al. IGFBP-4 is an inhibitor of canonical Wnt signalling required for cardiogenesis. Nature 2008; 454: 345-349.
https://doi.org/10.1038/nature07027
14. BELFIORE A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 2007; 13: 671-686.
https://doi.org/10.2174/138161207780249173
15. FRASCA F, PANDINI G, SCIACCA L, PEZZINO V, SQUATRITO S, BELFIORE A et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 2008; 114: 23-37.
https://doi.org/10.1080/13813450801969715
16. DE MEYTS P. Insulin and its receptor: structure, function and evolution. Bioessays 2004; 26: 1351-1362.
https://doi.org/10.1002/bies.20151
17. DE SOUZA AT, HANKINS GR, WASHINGTON MK, ORTON TC, JIRTLE RL. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 1995; 11: 447-449.
https://doi.org/10.1038/ng1295-447
18. POLLAK M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-928.
https://doi.org/10.1038/nrc2536
19. OSBORNE CK, BOLAN G, MONACO ME, LIPPMAN ME. Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proc Natl Acad Sci U S A 1976; 73: 4536-4540.
https://doi.org/10.1073/pnas.73.12.4536
20. HEUSON JC, LEGROS N, HEIMANN R. Influence of insulin administration on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in intact, oophorectomized, and hypophysectomized rats. Cancer Res 1972; 32: 233-238.
21. POLLAK MN, PERDUE JF, MARGOLESE RG, BAER K, RICHARD M. Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Lett 1987; 38: 223-230.
https://doi.org/10.1016/0304-3835(87)90218-7
22. MYAL Y, SHIU RP, BHAUMICK B, BALA M. Receptor binding and growth-promoting activity of insulin-like growth factors in human breast cancer cells (T-47D) in culture. Cancer Res 1984; 44 (12 Pt 1): 5486-5490.
23. SELL C, RUBINI M, RUBIN R, LIU JP, EFSTRATIADIS A, BASERGA R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci U S A 1993; 90: 11217-11221.
https://doi.org/10.1073/pnas.90.23.11217
24. MA J, POLLAK MN, GIOVANNUCCI E, CHAN JM, TAO Y, HENNEKENS CH et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999; 91: 620-625.
https://doi.org/10.1093/jnci/91.7.620
25. GIOVANNUCCI E, POLLAK MN, PLATZ EA, WILLETT WC, STAMPFER MJ, MAJEED N et al. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 2000: 345-349.
26. WU Y, CUI K, MIYOSHI K, HENNIGHAUSEN L, GREEN JE, SETSER J et al. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res 2003; 63: 4384-4388.
27. INGLE JN, SUMAN VJ, KARDINAL CG, KROOK JE, MAILLIARD JA, VEEDER MH et al. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 1999; 85: 1284-1292.
https://doi.org/10.1002/(SICI)1097-0142(19990315)85:6<1284::AID-CNCR10>3.0.CO;2-P
28. GOYA M, MIYAMOTO S, NAGAI K, OHKI Y, NAKAMURA K, SHITARA K et al. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res 2004; 64: 6252-6258.
https://doi.org/10.1158/0008-5472.CAN-04-0919
29. DIVISOVA J, KUIATSE I, LAZARD Z, WEISS H, VREELAND F, HADSELL DL, et al. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat 2006; 98: 315-327.
https://doi.org/10.1007/s10549-006-9168-1
30. LACY MQ, ALSINA M; FONSECA R, PACCAGNELLA ML, MELVIN CL, YIN D et al. Phase I, Pharmacokinetic and pharmacodynamic study of the anti-insulin like growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 2008; 26: 3196-3203.
https://doi.org/10.1200/JCO.2007.15.9319
31. HALUSKA P, SHAW HM, BATZEL GN, YIN D, MOLINA JR, MOLIFE LR et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007; 13: 5834-5840.
https://doi.org/10.1158/1078-0432.CCR-07-1118
32. KARP DD, PAZ-ARES LG, NOVELLOS S, HALUSKA P, GARLAND L, CARDENAL F et al. High activity of the anti-IGF-IR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC. J Clin Oncol 2008; 26 (Suppl), 8015.
https://doi.org/10.1200/jco.2008.26.15_suppl.8015
33. TOLCHER AW, ROTHENBERG ML, RODON J, DELBEKE D, PATNAIK A, NGUYEN L et al. A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. J Clin Oncol 2007 25 (Suppl) 3002.
https://doi.org/10.1200/jco.2007.25.18_suppl.3002
34. MOREAU P, HULIN C, FACON T, BOCCADORO M, MERY-MIGNARD D, DESLANDES A et al. Phase I study of AVE1642 anti IGF-1R monoclonal antibody in patients with advanced multiple myeloma. Proceedings of ASH 2007, abstract 1166.
https://doi.org/10.1182/blood.V110.11.1166.1166
35. TOLCHER AW, PATNAIK A, TILL E, TAKIMOTO CH, PAPADOPOULOS KP, MASSARD C et al. A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R antagonist, in patients with advanced solid tumor. J Clin Oncol 2008; 26 (Suppl), 3582.
https://doi.org/10.1200/jco.2008.26.15_suppl.3582
36. HIDALGO M, TIRADO GÓMEZ M, LEWIS N, VUKY JL, TAYLOR G, HAYBURN JL et al. A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 in advanced solid tumor patients in a q2 wk schedule. J Clin Oncol 2008; 26 (Suppl), 3520.
https://doi.org/10.1200/jco.2008.26.15_suppl.3520
37. RODON J, PATNAIK A, STEIN M, TOLCHER A, NG C, DIA C et al. A phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer. J Clin Oncol 2007; 26 (Suppl), 3590.
https://doi.org/10.1200/jco.2007.25.18_suppl.3590
38. POLLAK MN, SCHERNHAMMER ES, HANKINSON SE. Insulin-like growth factors and neoplasia. Nature Rev Cancer 2004; 4, 505-518.
https://doi.org/10.1038/nrc1387
39. DEL RINCON JP, LIDA K, GAYLINN BD, MCCURDY CE, LEITNER JW, BARCOUR LA et al. Growth hormone regulation of p85 expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance. Diabetes 2007; 56, 1638-1646.
https://doi.org/10.2337/db06-0299
40. HALUSKA P, CARBONI JM, LOEGERING DA, LEE FY, WITTMAN M, SAULNIER MG et al. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res 2006; 66: 362-371.
https://doi.org/10.1158/0008-5472.CAN-05-1107
41. JI QS, MULVIHILL MJ, ROSENFELD-FRANKLIN M, COOKE A, FENG L, MARK G et al. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. Mol Cancer Ther 2007; 6: 2158-2167.
https://doi.org/10.1158/1535-7163.MCT-07-0070
42. ZIMMERMANN K, WITTMAN MD, SAULNIER MG, VELAPARTHI U, LANGLEY DR, SANG X et al. Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors. Bioorg Med Chem Lett 2008; 18: 4075-4080.
https://doi.org/10.1016/j.bmcl.2008.05.104
43. MULVIHILL MJ, JI QS, COATE HR, COOKE A, DONG H, FENG L et al. Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors. Bioorg Med Chem 2008; 16: 1359-1375.
https://doi.org/10.1016/j.bmc.2007.10.061
44. HOFMANN F, GARCIA-ECHEVERRÍA C. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov. Today 2005; 10: 1041-1047.
https://doi.org/10.1016/S1359-6446(05)03512-9
45. VASILCANU R, VASILCANU D, ROSERNGREN L, NATALISHVILI N, SEHAT B, YIN S et al. Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and b-arrestin1. Oncogene 2008; 27: 1629-1638.
https://doi.org/10.1038/sj.onc.1210797
46. SHAW RJ, LAMIA KA, VASQUEZ D, KOO SH, BARDEESY N, DEPINHO RA et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310: 1642-1646.
https://doi.org/10.1126/science.1120781
47. DOWLING RJ, ZAKIKHANI M, FANTUS IG, POLLAK M, SONENBERG N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67: 10804-10812.
https://doi.org/10.1158/0008-5472.CAN-07-2310
48. ZAKIKHANI M, DOWLING R, FANTUS IG, SONENBERG N, POLLAK M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66: 10269-10273.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución-CompartirIgual 4.0.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
